NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 23-cv-02221 is on behalf of persons and entities that purchased or otherwise acquired DermTech securities between March 8, 2021 and November 3, 2022, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the "Exchange Act").
If you are a shareholder who purchased or otherwise acquired DermTech securities during the Class Period, you have until December 15, 2023, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
[Click here for information about joining the class action]
DermTech is a molecular diagnostic company that develops and markets non-invasive genomics tests to aid the ...